Advertisement
Canada markets closed
  • S&P/TSX

    22,167.03
    +59.95 (+0.27%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • DOW

    39,807.37
    +47.29 (+0.12%)
     
  • CAD/USD

    0.7384
    -0.0002 (-0.03%)
     
  • CRUDE OIL

    83.11
    -0.06 (-0.07%)
     
  • Bitcoin CAD

    95,155.29
    -569.01 (-0.59%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,254.80
    +16.40 (+0.73%)
     
  • RUSSELL 2000

    2,124.55
    +10.20 (+0.48%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • NASDAQ

    16,379.46
    -20.06 (-0.12%)
     
  • VOLATILITY

    13.01
    0.00 (0.00%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • NIKKEI 225

    40,369.44
    +201.37 (+0.50%)
     
  • CAD/EUR

    0.6832
    -0.0011 (-0.16%)
     

ADMA Biologics Third Quarter 2022 Earnings: Beats Expectations

ADMA Biologics (NASDAQ:ADMA) Third Quarter 2022 Results

Key Financial Results

  • Revenue: US$41.1m (up 99% from 3Q 2021).

  • Net loss: US$14.9m (loss narrowed by 16% from 3Q 2021).

  • US$0.076 loss per share (improved from US$0.13 loss in 3Q 2021).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

ADMA Biologics Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 19%. Earnings per share (EPS) also surpassed analyst estimates by 4.0%.

Looking ahead, revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.

ADVERTISEMENT

Performance of the American Biotechs industry.

The company's shares are up 21% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 1 warning sign for ADMA Biologics that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here